Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: Effect of terpene trilactones and flavonols

Drug Metabolism and Disposition

Volumn 37, Issue 9, 2009, Pages 1931-1937

  Lau, Aik Jiang ^a   Chang, Thomas K H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGLYCONE; AMFEBUTAMONE; BILOBALIDE; CYTOCHROME P450 2B6; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; ISOQUERCITRIN; ISORHAMNETIN; KAEMPFEROL; RADAFAXINE; RUTOSIDE;

ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG HYDROXYLATION; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; BUPROPION; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOLS; GINKGO BILOBA; GLYCOSIDES; HUMANS; HYDROXYLATION; KINETICS; LACTONES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PLANT EXTRACTS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TERPENES;

GINKGO BILOBA; NICOTIANA TABACUM;

EID: 70349142732     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028118     Document Type: Article

References (40)

1. Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, and Vermeulen NP (2007) Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 235:83-91. (Pubitemid 46669770)
2. Bedir E, Tatli II, Khan RA, Zhao J, Takamatsu S, Walker LA, Goldman P, and Khan IA (2002) Biologically active secondary metabolites from Ginkgo biloba. J Agric Food Chem 50:3150-3155.
3. Beyens MN, Guy C, Mounier G, Laporte S, and Ollagnier M (2008) Serious adverse reactions of bupropion for smoking cessation. Analysis of the French pharmacovigilance database from 2001 to 2004. Drug Safety 31:1017-1026.
4. Bieger J, Cermak R, Blank R, de Boer VC, Hollman PC, Kamphues J, and Wolffram S (2008) Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 138:1417-1420.
5. Cermak R and Wolffram S (2006) The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab 7:729-744. (Pubitemid 44509679)
6. Chang TKH, Bandiera SM, and Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31:7-10.
7. Chang TKH, Chen J, and Yeung EY (2006) Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Toxicol Appl Pharmacol 213:18-26.
8. Chang TKH, Weber GF, Crespi CL, and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637.
9. Dwoskin LP, Rauhut AS, King-Pospisil KA, and Bardo MT (2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178-207.
10. Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, and Mueller MJ (2008) Daily quercetin supplementation dose-dependently increase plasma quercetin concentrations in healthy humans. J Nutr 138:1615-1621.
11. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230. (Pubitemid 30747333)
12. Foti RS, Wahlstrom JL, and Wienkers LC (2007) The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Dispos 35:185-188.
13. Gardiner P, Graham RE, Legedza AT, Eisenberg DM, and Phillips RS (2006) Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 166:1968-1974. (Pubitemid 44537176)
14. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306. (Pubitemid 29376373)
15. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, and Court MH (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238. (Pubitemid 38530514)
16. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183. (Pubitemid 30747325)
17. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, and Zanger UM (2008) Aberrant splicing caused by single nucleotide polymorphism c. 516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325:284-292.
18. Kim H, Kim KB, Ku HY, Park SJ, Park SJ, Choi H, Moon JK, Park BS, Kim JH, Yea SS, et al. (2008) Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China. Drug Metab Dispos 36:1010-1015. (Pubitemid 351717457)
19. Lewis DFV (2000) On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Towards the prediction of human P450 substrate specificity and metabolism. Biochem Pharmacol 60:293-306.
20. Manach C, Williamson G, Morand C, Scalbert A, and Rémésy C (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S-242S.
21. Nakajima M, Yoshida R, Shimada N, Yamazaki H, and Yokoi T (2001) Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 29:1110-1113. (Pubitemid 32660529)
22. Pekthong D, Martin H, Abadie C, Bonet A, Heyd B, Mantion G, and Richert L (2008) Differential inhibition of rat and human hepatic cytochrome P450 by Andrographis paniculata extract and andrographolide. J Ethnopharmacol 115:432-440.
23. Piver B, Berthou F, Dreano Y, and Lucas D (2003) Differential inhibition of human cytochrome P450 enzymes by ε-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci 73:1199-1213. (Pubitemid 36733564)
24. Ramassamy C, Longpré F, and Christen Y (2007) Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr Alzheimer Res 4:253-262. (Pubitemid 47025423)
25. Seo KA, Kim H, Ku HY, Ahn HJ, Park SJ, Bae SK, Shin JG, and Liu KH (2008) The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. Chem Biol Interact 174:141-146.
26. Stiborová M, Borek-Dohalská L, Hodek P, Mráz J, and Frei E (2002) New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch Biochem Biophys 403:41-49. (Pubitemid 34848276)
27. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, and Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274:6043-6046. (Pubitemid 29111006)
28. Talakad JC, Kumar S, and Halpert JR (2009) Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos 37:644-650.
29. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, and Pelkonen O (2004) Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 32:626-631. (Pubitemid 38668155)
30. Turpeinen M, Raunio H, and Pelkonen O (2006) The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab 7:705-714. (Pubitemid 44509677)
31. van Beek TA and Montoro P (2009) Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J Chromatogr A 1216:2002-2032.
32. Volak LP, Ghirmai S, Cashman JR, and Court MH (2008) Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 36:1594-1605.
33. von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, and Greenblatt DJ (2004) Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Phamacol 56:1039-1044.
34. Vuppugalla R, Chang SY, Zhang H, Marathe PH, and Rodrigues DA (2007) Effect of commonly used organic solvents on the kinetics of cytochrome P450 2B6- and 2C8-dependent activity in human liver microsomes. Drug Metab Dispos 35:1990-1995. (Pubitemid 350005206)
35. Walsky RL, Astuccio AV, and Obach RS (2006) Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 46:1426-1438. (Pubitemid 44704203)
36. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660. (Pubitemid 38668158)
37. Wiczkowski W, Romaszko J, Bucinski A, Szawara-Nowak D, Honke J, Zielinski H, and Piskula MK (2008) Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J Nutr 138:885-888. (Pubitemid 351571587)
38. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
39. Wójcicki J, Gawrońska-Szklarz B, Bieganowski W, Patalan M, Smulski HK, Samochowiec L, and Zakrzewski J (1995) Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers. Materia Medica Polona 27:141-146. (Pubitemid 26381189)
40. Zou L, Harkey MR, and Henderson GL (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71:1579-1589. (Pubitemid 34808718)